| Similar Articles |
|---|
 |
Chemistry World
January 20, 2012
Sarah Houlton |
Takeda slashes 10% of its workforce This represents about 10% of its workforce, and the cuts will be made in research, commercial and admin sections of the business.   |
Chemistry World
September 22, 2006 |
Altana Sells Off Pharma Division The German pharmaceuticals and chemicals group Altana has sold its entire pharmaceutical business -- Altana Pharma -- to Danish drug company Nycomed. |
Chemistry World
May 3, 2013
Phillip Broadwith |
Judge reverses jury decision over $6.5m Takeda payout A judge has thrown out the jury's verdict in a case between Japanese drugmaker Takeda and a US man who claims that the company's drug caused his bladder cancer. |
Chemistry World
June 4, 2015
Phillip Broadwith |
Takeda to consolidate vaccines business in Boston Japanese pharma firm Takeda plans to close three US sites and move the headquarters of its vaccines business unit to the pharmaceutical hub in the Boston and Cambridge area of Massachusetts. |
Chemistry World
May 11, 2015
Phillip Broadwith |
Takeda offers $2.4bn to settle diabetes litigation Japanese drug company Takeda has put aside $2.7 billion to cover settlements of US product liability court cases relating to its diabetes drug Actos (pioglitazone). |
The Motley Fool
February 22, 2005
Rich Duprey |
Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%. |
The Motley Fool
September 2, 2010
Luke Timmerman |
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical. |
Chemistry World
November 7, 2012
Andrew Turley |
Takeda buys Envoy for $140m The move gives Takeda access to Envoy's 'BacTrap' technology for labeling and extracting the protein-making components of specific types of cells. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
The Motley Fool
July 6, 2007
Brian Lawler |
Medicines Decides Not to Share The Medicines Company reacquires its own drug. Until now, privately held European specialty pharma Nycomed has marketed Angiomax in Europe. Investors, take note. |
Chemistry World
April 11, 2014
Andy Extance |
Missing safety risk emails draw $9bn Actos fine A US jury has fined Takeda and Eli Lilly $9 billion for causing a man's bladder cancer with their diabetes drug Actos (pioglitazone). |
Pharmaceutical Executive
September 1, 2008
Walter Armstrong |
The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Productivity, Reputation are Keys to Global Leadership As CEO of Japan's largest pharmaceutical company and chair of Keizai Doyukai representing Japan's corporate business community, Yasuchika Hasegawa has the platform to pursue a two-pronged agenda that artfully fuses global and domestic priorities. |
Chemistry World
June 14, 2013
Phillip Broadwith |
Pfizer and Takeda win $2.15bn in patent payout Pfizer and Takeda will share a $2.15 billion settlement after suing generic drugmakers Teva and Sun Pharmaceuticals for patent infringement. |
Pharmaceutical Executive
February 1, 2014
William Looney |
Takeda' Oncology Taskmaster Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge; and a lead position in the hotly contested search to make cancer a treatable disease. |
Chemistry World
September 29, 2009
Sarah Houlton |
Abbott wins the race for Solvay's pharma business US-based pharmaceutical firm Abbott has continued its recent buying spree and bought Solvay's pharmaceutical division in a deal worth 5.2 billion euros or 4.7 billion. |
The Motley Fool
March 20, 2008
Brian Orelli |
Abbott and Takeda's Partnership TAPed Out It looks like Abbott Laboratories and Takeda will be ending their 30-year joint partnership with a 50/50 split. |
The Motley Fool
July 7, 2004
Brian Gorman |
Acusphere Makes a Friend The small firm announced that it sealed a $70 million partnership for AI-700, its experimental ultrasound contrast agent, with privately held European pharmaceutical concern Nycomed. Shares of Acusphere soared 20% on news of the pact. |
Chemistry World
May 30, 2012 |
Takeda buys into Brazil for 540m reals Brazilian company Multilab made sales of BRL140 million in 2011, primarily from generics and over-the-counter branded products, including its leading cold and flu brand Multigrip. |
BusinessWeek
May 26, 2011
Caroline Winter |
Bid & Ask: The Deals of the Week Deals of the Week: Takeda spends billions bracing for its Actos patent to expire... A U.S. IPO for Russia's Yandex pulls in $1.3 billion... Labelux acquires luxury shoemaker Jimmy Choo... |
The Motley Fool
November 30, 2006
Brian Lawler |
Durect's Pain-Free Deal A partnership deal has investors in the small specialty pharma excited. |
Pharmaceutical Executive
March 1, 2007
Maraldo & Lister |
Back Page: Let's Get Gutsy Pharma gets no respect from the public. But instead of complaining about it, industry should stop whining and start leading. Here's a seven-point starter kit. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Little Up Front and a Lot Later for Cell Genesys Small development-stage drugmaker Cell Genesys announces that it has inked a partnership deal for its lead drug with pharmaceutical giant Takeda. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Japanese pharma opens compound vaults Japanese pharmaceutical companies are opening up their libraries of experimental compound as part of a new partnership program. The initiative aims to find new drugs for malaria, tuberculosis and neglected tropical diseases. |
Pharmaceutical Executive
February 1, 2006
Chandler & Chicco |
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways |
